MTMiyu Tanaka

Miyu Tanaka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Miyu Tanaka has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Junzo Hamanishi

    Department of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University Kyoto Japan

    2 shared publications
  • Koji Yamanoi

    Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, Kyoto, Japan

    2 shared publications
  • Sachiko Kitamura

    Department of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University Kyoto Japan

    2 shared publications
  • Yoshitsugu Chigusa

    Department of Gynecology and Obstetrics, Graduate School of Medicine Kyoto University Kyoto Japan

    2 shared publications
  • Akihito Horie

    Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, 54 Shogoinkawahara-cho, Sakyo-ku, Kyoto city, Kyoto, 606-8507, Japan

    1 shared publication
  • Akihito Horie

    Department of Gynecology and Obstetrics Kyoto University Graduate School of Medicine Kyoto Japan

    1 shared publication

Latest Publications

  • Open Access

    Hypercoiling and Single Umbilical Artery Associated With Fetal Placental Malperfusion and Growth Restriction: A Case Report

    by Masaya Tanimura, Tomo Yamagata, Moyu Matsui, Yusuke Yamaoka, Kohei Ida, Shohei Nakamura, Miyu Tanaka, Motonori Matsubara

    Hypercoiling of the umbilical cord can lead to fetal growth restriction and stillbirth because the cord is vulnerable to blood flow disturbances caused by external forces. A single umbilical artery (SUA) is a relatively common abnormality; however, isolated SUA is associated with fetal growth restriction and stillbirth. We report a case of fetal growth restriction with both SUA and hypercoiling. A 27‐year‐old primigravida was evaluated at 37 weeks of gestation. Prenatal ultrasonography revealed a small‐for‐gestational‐age fetus with a single umbilical artery and a hypercoiled umbilical cord. Continuous fetal monitoring was initiated upon admission. Cardiotocography demonstrated recurrent prolonged decelerations, necessitating an emergency cesarean section. Placental histopathology revealed fetal vascular malperfusion with hyalinized avascular villi and thrombotic occlusion of one umbilical artery, indicating disturbed fetoplacental circulation likely related to SUA and hypercoiling. The coexistence of hypercoiling and a single umbilical artery was associated with the risk of fetal vascular malperfusion and growth restriction. Careful antenatal surveillance and timely delivery are essential to prevent adverse perinatal outcomes in multiple umbilical cord anomalies.


  • High‐grade vaginal intraepithelial neoplasia after hysterectomy for high‐grade cervical intraepithelial neoplasia: Is hysterectomy a “definitive” treatment compared to conization?

    by Miyu Tanaka, Koji Yamanoi, Mana Taki, Sachiko Kitamura, Masumi Sunada, Yoshitsugu Chigusa, Akihito Horie, Ken Yamaguchi, Junzo Hamanishi, Masaki Mandai

    Aim: We investigated the frequency of early recurrence of vaginal intraepithelial neoplasia grade 2/3 (VaIN 2/3) (within 2 years) after hysterectomy for cervical intraepithelial neoplasia grade 3 (CIN3). The characteristics of the clinicopathological factors common to them were explored including different surgical methods.Methods: As a retrospective observational study, a total of 647 CIN3 patients were divided into a conization and hysterectomy group (C group, n = 492; H group, n = 155), and HSIL (CIN2/3 or VaIN2/3) recurrence within 2 years after surgery was evaluated. A stratified analyses was performed. Surgical methods were divided into trans‐abdominal, trans‐vaginal, and laparoscopic.Results: The recurrence of VaIN3 was detected in four cases (2.6%) in the H group, which was similar to that of CIN2/3 in the C group, 12 out of 491 patients (2.4%). The patients who developed VaIN3 were significantly older than those who did not (median, VaIN3: 71.0; VaIN1 and less: 48.0; p < 0.0001). All VaIN3 cases were detected within 5 months, although majority of cases were negative in the margin (3/4 cases; margin negative). The method of hysterectomy was not related to the VaIN3 recurrence.Conclusion: For CIN3 patients for whom hysterectomy is the main treatment, VaIN3 can develop in 2.6% within very shortly after operation even if surgical margin was negative. The elder the age, the higher the risk of early recurrence could be. Laparoscopic surgery is considered to be acceptable methods of hysterectomy.


  • Open Access

    A 36 kg Giant Ovarian Fibroma with Meigs Syndrome: A Case Report and Literature Review of Extremely Giant Ovarian Tumor

    by Miyu Tanaka, Koji Yamanoi, Sachiko Kitamura, Naoki Horikawa, Yoshitsugu Chigusa, Akihito Horie, Ken Yamaguchi, Junzo Hamanishi, Eiji Kondoh, Masaki Mandai

    Ovarian tumors can get extremely giant to occupy the whole abdominal cavity. We report a case of 36kg solid ovarian tumor, which was the largest ovarian solid tumor that have been ever reported. A 54-year-old woman presented to our hospital with a chief complaint of markedly distended abdominal wall. Preoperative imaging examinations revealed that most of the tumor was uniform and its density was like that of subcutaneous fat. Pleural effusion was detected in the right thoracic region. We organized a multidisciplinary team and successfully resected the right adnexa. The patient had an uneventful postoperative course, and she was discharged on the 7th postoperative day and diagnosed with a fibroma of the ovary with Meigs syndrome. A comprehensive literature search revealed 48 cases of extremely giant ovarian tumor in these 20 years. Six out of 48 cases are solid. Twelve out of 48 cases are malignant or borderline malignant, and patients age and tumor size/weight were not related to the frequency of malignancy/borderline malignancy. As many as 4 out of 48 patients died before their first hospital visit or early after surgery. Clinicians should consider a considerable high mortality and frequency of severe surgical complications when planning the treatment strategy for extremely giant ovarian tumors.